Marketing of antipsychotic drugs targeted doctors of Medicaid patients, report saysBMJ 2012; 345 doi: http://dx.doi.org/10.1136/bmj.e6633 (Published 02 October 2012) Cite this as: BMJ 2012;345:e6633
- Bob Roehr
- 1Washington, DC
Psychiatrists serving the 205 000 low income people covered by the Medicaid program in Washington, DC, disproportionately benefited from gifts and payments from pharmaceutical companies, compared with other local physicians, a study shows.
In addition, children covered by Medicaid, a principal focus of the program, were twice as likely as all Americans to be prescribed antipsychotic drugs. About one child in 10 was prescribed that class of drugs.
Those two associations were gleaned from an analysis of marketing data that pharmaceutical companies reported to the government of the District of Columbia under the AccessRx Act, which was passed in …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial